AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21406077 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision in HIV-1 uninfected male partners
Number of subjects: 3354
Study 21406078 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS)
Number of subjects: 26
Study 21406078 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 26
Study 21406109 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of standardized Ginkgo biloba two times per day for 12 weeks
Number of subjects: 12
Study 21406512 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prescription for patients producing discoloured sputum
Number of subjects: 3402
Study 21406512 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prescription for patients producing clear/white sputum
Number of subjects: 3402
Study 21406512 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for patients producing yellow sputum
Number of subjects: 3402
Study 21406512 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for patients producing green sputum
Number of subjects: 3402
Study 21406512 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for patients feeling unwell
Number of subjects: 3402
Study 21406512 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for patients producing discoloured sputum and feeling unwell
Number of subjects: 3402
Study 21406610 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva-derived biomarkers and periodontal pathogens analysis
Number of subjects: 100
Study 21406610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low biofilm and biomarker levels
Number of subjects: 100
Study 21406610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster membership based on salivary biomarkers and biofilm pathogens
Number of subjects: 100
Study 21407181 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-15b
Number of subjects: 22
Study 21407181 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-21
Number of subjects: 22
Study 21407181 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-203
Number of subjects: 22
Study 21407181 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-486-5p
Number of subjects: 22
Study 21407181 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-let-7a
Number of subjects: 22
Study 21408154 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise (10 supervised 30-min treadmill sessions over 2 weeks)
Number of subjects: 12
Study 21408154 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise
Number of subjects: 12
Study 21410411 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hepatitis B virus-associated membranous nephritis
Number of subjects: 0
Study 21410411 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21410954 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) provided by community health workers (CHWs) for unsupervised treatment at home
Number of subjects: 244
Study 21410954 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 244
Study 21410960 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram up to 50 mg
Number of subjects: 60
Study 21410972 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL12 expression in epithelial tumor cells
Number of subjects: 183
Study 21410972 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL12 expression levels
Number of subjects: 183
Study 21410972 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL12 expression impact on survival
Number of subjects: 183
Study 21411559 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid antibody positive (n=245)
Number of subjects: 3593
Study 21411559 — intervention group
Group type: COMPARATOR
Intervention: Thyroid antibody negative (n=3348)
Number of subjects: 3593
Study 21411618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-choline diet
Number of subjects: 72
Study 21411618 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 72
Study 21411618 — intervention group
Group type: COMPARATOR
Intervention: PEMT polymorphism rs12325817
Number of subjects: 72
Study 21411618 — intervention group
Group type: COMPARATOR
Intervention: Human liver samples
Number of subjects: 72
Study 21411618 — intervention group
Group type: COMPARATOR
Intervention: Ratio of DHA-PtdCho to PtdCho in plasma
Number of subjects: 72
Study 21412372 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoassay testing (index test)
Number of subjects: 1000
Study 21412372 — intervention group
Group type: COMPARATOR
Intervention: LC/MS/MS (reference test)
Number of subjects: 1000
Study 21414193 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan 10 mg (single oral dose)
Number of subjects: 80
Study 21414495 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg at week 0, then 40 mg every other week from week 1)
Number of subjects: 152
Study 21414495 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (for patients previously on etanercept)
Number of subjects: 152
Study 21414495 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (for patients previously on MTX)
Number of subjects: 152
Study 21414495 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (for patients previously on NB-UVB)
Number of subjects: 152
Study 21414495 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 152
Study 21414634 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 25
Study 21414634 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitored Blood Glucose (SMBG)
Number of subjects: 25
Study 21414654 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Number of subjects: 27
Study 21415059 — intervention group
Group type: EXPERIMENTAL
Intervention: mfPERG (multifocal transient pattern electroretinography)
Number of subjects: 23
Study 21415076 — intervention group
Group type: EXPERIMENTAL
Intervention: Layer-specific myocardial deformation analysis (endocardial, mid-myocardial, epicardial strain)
Number of subjects: 132
Study 21415076 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocardial circumferential strain
Number of subjects: 132
Study 21415076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperenhancement analysis by ceMRI
Number of subjects: 132
Study 21415076 — intervention group
Group type: EXPERIMENTAL
Intervention: Total wall thickness strain
Number of subjects: 132
Study 21415076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperenhancement by ceMRI
Number of subjects: 132
Study 21415315 — intervention group
Group type: EXPERIMENTAL
Intervention: Home short daily hemodialysis (SDHD) 6 times/week
Number of subjects: 235
Study 21415456 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SES African American children
Number of subjects: 272
Study 21415776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² (first five patients 60 mg/m²) and pemetrexed 500 mg/m² every 21 days for three cycles with chest radiotherapy to 66 Gy, followed by docetaxel 75 mg/m² every 21 days for three cycles.
Number of subjects: 28
Study 21416508 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy-based assessment
Number of subjects: 7479
Study 21416508 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based assessment
Number of subjects: 7479
Study 21418581 — intervention group
Group type: EXPERIMENTAL
Intervention: Global clinical evaluations and Brøset Violence Checklist (BVC) at admittance
Number of subjects: 118
Study 21418581 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of segregation
Number of subjects: 118
Study 21418581 — intervention group
Group type: COMPARATOR
Intervention: Actuarial data
Number of subjects: 118
Study 21419408 — intervention group
Group type: EXPERIMENTAL
Intervention: SpyGlass system
Number of subjects: 75
Study 21419775 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of AS03- or MF59-adjuvanted vaccines in immunocompetent children
Number of subjects: 126
Study 21419775 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of AS03- or MF59-adjuvanted vaccines in immunocompromised children
Number of subjects: 126
Study 21419775 — intervention group
Group type: COMPARATOR
Intervention: Convalescent children (natural infection)
Number of subjects: 126
Study 21421838 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipients after allogeneic stem cell transplantation (SCT)
Number of subjects: 21
Study 21421838 — intervention group
Group type: COMPARATOR
Intervention: Donors at transplant
Number of subjects: 21
Study 21421838 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR repertoire analysis
Number of subjects: 21
Study 21421840 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal peripheral B cells in HCV(+)MC(+) patients
Number of subjects: 0
Study 21421840 — intervention group
Group type: EXPERIMENTAL
Intervention: CD27(+)CD21(low) B-cell subset
Number of subjects: 0
Study 21421840 — intervention group
Group type: COMPARATOR
Intervention: CD27(+)CD21(high) B-cell subset
Number of subjects: 0
Study 21422405 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 0
Study 21422474 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-specific CD8+ T-cell clones derived from HIV-reactive CD28+CD8+ T-cell lines
Number of subjects: 7
Study 21425150 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (CLO) 4 mg/m², administered as a 1-hour intravenous infusion daily for 5 days every 28 days (maximum 6 cycles)
Number of subjects: 31
Study 21425150 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (CLO) in rituximab-refractory patients
Number of subjects: 31
Study 21425150 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (CLO)
Number of subjects: 31
Study 21425247 — intervention group
Group type: EXPERIMENTAL
Intervention: Novartis MF59-adjuvanted H1N1v monovalent influenza vaccine
Number of subjects: 119
Study 21425247 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 119
Study 21425247 — intervention group
Group type: EXPERIMENTAL
Intervention: RA and PsA patients
Number of subjects: 119
Study 21425247 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28, BASDAI, and SLEDAI
Number of subjects: 119
Study 21426510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment with secondary hyperparathyroidism management
Number of subjects: 0
Study 21426510 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 21426511 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC) treatment, flexible daily dosage of 750-4500 mg
Number of subjects: 0
Study 21426511 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC) treatment
Number of subjects: 0
Study 21426546 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 219
Study 21426560 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary proteomic analyses using MALDI-TOF MS
Number of subjects: 10
Study 21426560 — intervention group
Group type: COMPARATOR
Intervention: Matched non-delirium patients after cardiac surgery
Number of subjects: 10
Study 21427395 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 5507
Study 21427395 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (compared within households)
Number of subjects: 5507
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial changes in cardiac output (CO)
Number of subjects: 23
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial changes in heart rate (HR)
Number of subjects: 23
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial changes in stroke volume (SV)
Number of subjects: 23
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging systolic longitudinal ventricular velocity of the septum (S's)
Number of subjects: 23
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging systolic longitudinal ventricular velocity of the lateral wall (S'l)
Number of subjects: 23
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging early diastolic longitudinal ventricular velocity of the lateral wall (E'l)
Number of subjects: 23
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging late diastolic longitudinal ventricular velocity of the septum (A's)
Number of subjects: 23
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging late diastolic longitudinal ventricular velocity of the lateral wall (A'l)
Number of subjects: 23
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric emptying rate (GER)
Number of subjects: 23
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and insulin concentrations
Number of subjects: 23
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiety
Number of subjects: 23
Study 21429209 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 23
Study 21429580 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (HF)
Number of subjects: 100
Study 21429580 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study 21431345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib and pegylated-IFNα (PEG-IFNα)
Number of subjects: 21
Study 21432592 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (target dose 0.5-1.2 mg/kg/day)
Number of subjects: 421
Study 21433272 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/hr infusion)
Number of subjects: 110
Study 21435246 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based lifestyle intervention program
Number of subjects: 25
Study 21435246 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators for lifestyle change
Number of subjects: 25
Study 21435246 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to lifestyle change
Number of subjects: 25
Study 21435513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 15147
Study 21436300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI)
Number of subjects: 427
Study 21436300 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic PAD participants
Number of subjects: 427
Study 21436454 — intervention group
Group type: EXPERIMENTAL
Intervention: CD40 agonist antibody combined with gemcitabine chemotherapy
Number of subjects: 0
Study 21436454 — intervention group
Group type: EXPERIMENTAL
Intervention: CD40 agonist antibody
Number of subjects: 0
Study 21436454 — intervention group
Group type: EXPERIMENTAL
Intervention: CD40-activated macrophages
Number of subjects: 0
Study 21436711 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment
Number of subjects: 16
Study 21436758 — intervention group
Group type: EXPERIMENTAL
Intervention: aEEG assessment within the first week
Number of subjects: 143
Study 21436758 — intervention group
Group type: EXPERIMENTAL
Intervention: aEEG assessment within the second week
Number of subjects: 143
Study 21436758 — intervention group
Group type: COMPARATOR
Intervention: Cerebral ultrasound assessment within the first week
Number of subjects: 143
Study 21436758 — intervention group
Group type: COMPARATOR
Intervention: Cerebral ultrasound assessment within the second week
Number of subjects: 143
Study 21437515 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) patients
Number of subjects: 261
Study 21437515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 261
Study 21437851 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound elastography (EUS elastography)
Number of subjects: 258
Study 21437851 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis by two expert doctors
Number of subjects: 258
Study 21437851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer variability analysis
Number of subjects: 258
Study 21437851 — intervention group
Group type: EXPERIMENTAL
Intervention: Average-hue histogram analysis of EUS elastography videos
Number of subjects: 258
Study 21439051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 254
Study 21439051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 21439671 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 3224
Study 21440300 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal medical food
Number of subjects: 112
Study 21440300 — intervention group
Group type: COMPARATOR
Intervention: Standard PNVs
Number of subjects: 112
Study 21440503 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg/week and rituximab 375 mg/m(2) per week for 4 weeks, then rituximab every other 28-day cycle for a total of 12 cycles.
Number of subjects: 71
Study 21440503 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus and rituximab in rituximab-sensitive patients.
Number of subjects: 71
Study 21440503 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus and rituximab in rituximab-refractory patients.
Number of subjects: 71
Study 21440503 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events in rituximab-sensitive patients.
Number of subjects: 71
Study 21440503 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events in rituximab-refractory patients.
Number of subjects: 71
Study 21440865 — intervention group
Group type: EXPERIMENTAL
Intervention: P×T (pressure-based hemodynamic factor) in patients with HFRE
Number of subjects: 274
Study 21440865 — intervention group
Group type: COMPARATOR
Intervention: P×T (pressure-based hemodynamic factor) in patients without HFRE
Number of subjects: 274
Study 21441100 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Guide to Health (WB-GTH) intervention
Number of subjects: 963
Study 21441399 — intervention group
Group type: EXPERIMENTAL
Intervention: Single urinary albumin excretion (UAE) measurement
Number of subjects: 4062
Study 21441399 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin excretion rate (AER) measurement
Number of subjects: 4062
Study 21441399 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoturbidimetry
Number of subjects: 4062
Study 21441399 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple UAE measurements (geometric mean)
Number of subjects: 4062
Study 21443558 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical periodontal examination and assessment of sperm quality according to WHO criteria.
Number of subjects: 75
Study 21443790 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based gene expression algorithm
Number of subjects: 640
Study 21443790 — intervention group
Group type: EXPERIMENTAL
Intervention: Microarray analysis of RNA samples
Number of subjects: 640
Study 21443790 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR analysis of CAD classifier genes
Number of subjects: 640
Study 21443790 — intervention group
Group type: EXPERIMENTAL
Intervention: Microarray cohort analysis
Number of subjects: 640
Study 21443790 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm development using RT-PCR analysis of 113 genes
Number of subjects: 640
Study 21443962 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination
Number of subjects: 2635
Study 21444917 — intervention group
Group type: EXPERIMENTAL
Intervention: Prephase chemotherapy followed by 3 courses of chemotherapy (for 6 patients with complete resection)
Number of subjects: 36
Study 21444917 — intervention group
Group type: EXPERIMENTAL
Intervention: Prephase chemotherapy followed by 6 courses of chemotherapy (for 30 patients without complete resection)
Number of subjects: 36
Study 21444917 — intervention group
Group type: COMPARATOR
Intervention: Stage I patients (incomplete resection)
Number of subjects: 36
Study 21445332 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement regulatory proteins mutations (MCP, CFI, CFH)
Number of subjects: 250
Study 21445332 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk variants in MCP or CFI
Number of subjects: 250
Study 21445332 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel mutation in MCP
Number of subjects: 250
Study 21445332 — intervention group
Group type: COMPARATOR
Intervention: Hypomorphic variants of MCP and CFI
Number of subjects: 250
Study 21446778 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban tosylate
Number of subjects: 21500
Study 21446779 — intervention group
Group type: EXPERIMENTAL
Intervention: Varespladib
Number of subjects: 6500
Study 21446779 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 6500
Study 21447161 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-lead ECG and advance emergency department (ED) notification
Number of subjects: 0
Study 21447161 — intervention group
Group type: COMPARATOR
Intervention: 3-lead ECG monitoring and alert to dispatch prior to hospital arrival
Number of subjects: 0
Study 21447161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass to PCI centre (with or without prehospital strategies)
Number of subjects: 0
Study 21447197 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified anteriolateral bent knee portal
Number of subjects: 83
Study 21447197 — intervention group
Group type: COMPARATOR
Intervention: Standard lateral midpatellar portal
Number of subjects: 83
Study 21447719 — intervention group
Group type: EXPERIMENTAL
Intervention: AS1409 at 15 μg/kg weekly
Number of subjects: 13
Study 21447834 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 559
Study 21447948 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 189
Study 21447948 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 189
Study 21448080 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 102
Study 21448080 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 102
Study 21448080 — intervention group
Group type: EXPERIMENTAL
Intervention: h-FABP
Number of subjects: 102
Study 21448080 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 102
Study 21448080 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP
Number of subjects: 102
Study 21448080 — intervention group
Group type: EXPERIMENTAL
Intervention: cystatin C
Number of subjects: 102